Deborah Honig
Adelaide Capital

Good morning, everyone. Thanks for joining us today. We have an update with Microbix, who just put out their Q2 numbers this morning. So hopefully, everyone's had a chance to review those.

With me on the call, I have Cameron Groome, CEO; Ken Hughes, COO; Jim Currie, CFO. I'm not sure if we're going to work off the presentation today, but as always, this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the presentation on the company's website. And there will be a Q&A section. So feel free to enter any questions you have in the Q&A box.

And with that out of the way, I'd like to turn the mic over to Cameron. Hi, Cameron.

Cameron Groome
President, CEO & Director

Good morning, Deborah. Thank you so much, and good morning, Ken and Jim. I just want to thank everybody on the call for joining us for this update call this morning. As everybody will have seen from our results in Q2, it's not a particularly pretty quarter. The revenues were well below our engineered breakeven point, which is about $5.5 million a quarter of revenues. So not unexpected to show a net loss, but we are continuing to control our costs well, but net losses are not what we get dressed up in the morning for even if controlled.

Some of that, and I'll ask Jim to speak to any specifics and address particular questions, but we have continued, of course, to see lower year-over-year